Bioelectronics Corp Stock Performance
| BIEL Stock | USD 0.0003 0.00 0.00% |
Bioelectronics Corp holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -3.17, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bioelectronics Corp are expected to decrease by larger amounts. On the other hand, during market turmoil, Bioelectronics Corp is expected to outperform it. Use Bioelectronics Corp sortino ratio and the relationship between the potential upside and day median price , to analyze future returns on Bioelectronics Corp.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Bioelectronics Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Bioelectronics Corp disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Bioelectronics |
Bioelectronics Corp Relative Risk vs. Return Landscape
If you would invest 0.03 in Bioelectronics Corp on September 16, 2024 and sell it today you would earn a total of 0.00 from holding Bioelectronics Corp or generate 0.0% return on investment over 90 days. Bioelectronics Corp is currently generating 1.7949% in daily expected returns and assumes 19.7363% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Bioelectronics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bioelectronics Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioelectronics Corp's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bioelectronics Corp, and traders can use it to determine the average amount a Bioelectronics Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0909
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | BIEL | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.74 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.79 actual daily | 35 65% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Bioelectronics Corp is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bioelectronics Corp by adding it to a well-diversified portfolio.
Bioelectronics Corp Fundamentals Growth
Bioelectronics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bioelectronics Corp, and Bioelectronics Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioelectronics Pink Sheet performance.
| Return On Asset | -0.34 | |||
| Profit Margin | (0.18) % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 52.16 M | |||
| Shares Outstanding | 24.71 B | |||
| Price To Sales | 30.73 X | |||
| Revenue | 1.61 M | |||
| EBITDA | (1.36 M) | |||
| Cash And Equivalents | 925 | |||
| Total Debt | 13.34 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (320.3 K) | |||
| Total Asset | 1.11 M | |||
| Retained Earnings | (28.41 M) | |||
| Current Asset | 1.11 M | |||
| Current Liabilities | 6.86 M | |||
About Bioelectronics Corp Performance
By examining Bioelectronics Corp's fundamental ratios, stakeholders can obtain critical insights into Bioelectronics Corp's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bioelectronics Corp is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. The company was incorporated in 2000 and is headquartered in Frederick, Maryland. BIOELECTRONICS CORP operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about Bioelectronics Corp performance evaluation
Checking the ongoing alerts about Bioelectronics Corp for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bioelectronics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bioelectronics Corp is way too risky over 90 days horizon | |
| Bioelectronics Corp has some characteristics of a very speculative penny stock | |
| Bioelectronics Corp appears to be risky and price may revert if volatility continues | |
| Bioelectronics Corp has high likelihood to experience some financial distress in the next 2 years | |
| Bioelectronics Corp currently holds 13.34 M in liabilities. Bioelectronics Corp has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bioelectronics Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Bioelectronics Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bioelectronics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bioelectronics to invest in growth at high rates of return. When we think about Bioelectronics Corp's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.61 M. Net Loss for the year was (289.82 K) with profit before overhead, payroll, taxes, and interest of 795.53 K. | |
| Bioelectronics Corp currently holds about 925 in cash with (320.3 K) of positive cash flow from operations. |
- Analyzing Bioelectronics Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioelectronics Corp's stock is overvalued or undervalued compared to its peers.
- Examining Bioelectronics Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bioelectronics Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioelectronics Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bioelectronics Corp's pink sheet. These opinions can provide insight into Bioelectronics Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Bioelectronics Pink Sheet
Bioelectronics Corp financial ratios help investors to determine whether Bioelectronics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bioelectronics with respect to the benefits of owning Bioelectronics Corp security.